Drug Profile


Alternative Names: A 3309; AJG 533

Latest Information Update: 03 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer Albireo AB; Albireo Pharma; EA Pharma
  • Class 2 ring heterocyclic compounds; Amides; Carboxylic acids; Laxatives; Small molecules; Sulfides; Sulfones; Thiazepines
  • Mechanism of Action Sodium-bile acid cotransporter-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Constipation
  • Phase II Irritable bowel syndrome
  • Discontinued Dyslipidaemias

Most Recent Events

  • 01 Feb 2017 Preregistration for Constipation in Japan (PO)
  • 03 Oct 2016 Albireo announces intention to submit NDA for elobixibat for use in chronic constipation to PMDA Japan in Q1 2017
  • 03 Oct 2016 Topline adverse events and efficacy data from a phase III trial in Constipation released by Albireo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top